Quantum Computing Inc Expands Into Pharma With INmune Bio Deal

INmune Bio and Quantum Computing Inc. are combining clinical data from four trials with QCi’s Dirac-3S quantum optimization machine to explore new uses for XPro1595, an investigational Alzheimer’s treatment. This collaboration marks QCi’s first commercial customer within the pharmaceutical and biotechnology sectors, extending quantum computing beyond its traditional applications, INmune Bio says.

The companies will analyze datasets to identify diseases sharing biological traits with those XPro targets, prioritizing conditions where trials could be accelerated; as INmune Bio CEO David Moss states, “This collaboration allows us to examine patient populations and biomarkers most likely to predict responses by analyzing large data sets.”

XPro Targets Inflammation in Alzheimer’s and Rare Diseases

INmune Bio is analyzing its extensive clinical dataset on Alzheimer’s and other diseases, accumulated over years of work with its investigational treatment XPro, using quantum computing. will combine data from pre-clinical research through four clinical trials to uncover relationships that could lead to new treatment indications and biomarkers. QCi’s Dirac-3S quantum optimization machine will be central to this effort, comparing results with conventional statistical and machine-learning methods to determine where quantum computing offers the greatest analytical advantage.